Partnering

At Zogenix, we intend to expand our pipeline of product candidates in our key focus areas of Central Nervous System (CNS) disorders and pain by:

- leveraging our proprietary DosePro™ technology by investigating proven drugs that can be paired with DosePro to enhance their benefits and commercial attractiveness, and

- in-licensing or acquiring other drug products and product candidates, with a focus on products and product candidates that utilize novel technologies to improve the profile of existing compounds.

In both cases, we plan to focus on marketed compounds whose commercial potential has been limited by safety concerns, relative efficacy or patient adherence.

In addition, we may further seek to capitalize on our DosePro technology by out-licensing it to potential partners seeking to enhance, differentiate, or extend the life cycle of their own injectable products.

Finally, we will also seek to establish partnerships with pharmaceutical companies or contract sales organizations to market and sell to a broader physician audience than can be reached by our planned sales force alone.

For further information about partnering opportunities, please contact us.